No.

Publication Date

Citing Article

1

2022

Abdelrahman K. A. A. Salama, Marija V. Trkulja, Emilio Casanova, Iris Z. Uras. Targeted Protein Degradation: Clinical Advances in the Field of Oncology, International Journal of Molecular Sciences. 2022; 23: 15440.  https://doi.org/10.3390/ijms232315440

2

2023

Kristina Viktorsson, Thorsten Rieckmann, Maximilian Fleischmann, Markus Diefenhardt, Stephanie Hehlgans, Franz Rödel. Advances in molecular targeted therapies to increase efficacy of (chemo)radiation therapy, Strahlentherapie und Onkologie. 2023; 199: 1091.  https://doi.org/10.1007/s00066-023-02064-y

3

2024

Soohyun Lee, Hwa‐Ryeon Kim, Yaejin Woo, Jiyoung Kim, Han Wool Kim, Ji Youn Park, Beomseon Suh, Yuri Choi, Jungmin Ahn, Je Ho Ryu, Jae‐Seok Roe, Jaewhan Song, Song Hee Lee. UBX‐390: A Novel Androgen Receptor Degrader for Therapeutic Intervention in Prostate Cancer, Advanced Science. 2024; 11: 2400398.  https://doi.org/10.1002/advs.202400398

4

2022

O. A. Koroleva, Yu. V. Dutikova, A. V. Trubnikov, F. A. Zenov, E. V. Manasova, A. A. Shtil, A. V. Kurkin. PROTAC: targeted drug strategy. Principles and limitations, Russian Chemical Bulletin. 2022; 71: 2310.  https://doi.org/10.1007/s11172-022-3659-z

5

2023

Rodrigo Sánchez Bayona, Manuel Alva Bianchi. Luminal breast cancer treatment beyond cell cycle inhibitors, Revisiones en Cáncer. 2023;   https://doi.org/10.20960/revcancer.00027

6

2023

Carmen Avendaño, J. Carlos Menéndez. 2023; 637.  https://doi.org/10.1016/B978-0-12-818549-0.00012-1

7

2024

Luís A. R. Carvalho, Bárbara B. Sousa, Daniel Zaidman, Hannah Kiely‐Collins, Gonçalo J. L. Bernardes. Design and Evaluation of PROTACs Targeting Acyl Protein Thioesterase 1, ChemBioChem. 2024; 25: e202300736.  https://doi.org/10.1002/cbic.202300736

8

2024

Jun Xia, James K.S. Norris, May-Li MacKinnon, Sam Butterworth. Proteolysis Targeting Chimeras (PROTACs): An Innovative Strategy for Targeted Protein Degradation and Disease Treatment, International Journal of Drug Discovery and Pharmacology. 2024; 100015.  https://doi.org/10.53941/ijddp.2024.100015

9

2023

Lara J. Bou Malhab, Habiba Alsafar, Saleh Ibrahim, Mohamed Rahmani. PROTACs: Walking through hematological malignancies, Frontiers in Pharmacology. 2023; 14: 1086946.  https://doi.org/10.3389/fphar.2023.1086946

10

2023

, Revolutionizing Drug Targeting Strategies: Integrating Artificial Intelligence and Structure-Based Methods in PROTAC Development, Pharmaceuticals. 2023; 16: 1649.  https://doi.org/10.3390/ph16121649

11

2025

Sowndharya M, Ramesh Joga, Kajal Gandhi, Sravani Yerram, Rajeev Singh Raghuvanshi, Saurabh Srivastava. Exploring the clinical trials, regulatory insights, and challenges of PROTACs in oncology, Seminars in Oncology. 2025; 52: 152339152339.  https://doi.org/10.1016/j.seminoncol.2025.152339

12

2023

Abhenil Mittal, Consolacion Molto Valiente, Faris Tamimi, Ilana Schlam, Sarah Sammons, Sara M. Tolaney, Paolo Tarantino. Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer, Cancers. 2023; 15: 2015.  https://doi.org/10.3390/cancers15072015

13

2024

Simon C. C. Lucas, Afshan Ahmed, S. Neha Ashraf, Argyrides Argyrou, Matthias R. Bauer, Gian Marco De Donatis, Sylvain Demanze, Frederik Eisele, Lucia Fusani, Andreas Hock, Ganesh Kadamur, Shuyou Li, Abigail Macmillan-Jones, Iacovos N. Michaelides, Christopher Phillips, Marie Rehnström, Magdalena Richter, Monica C. Rodrigo-Brenni, Fiona Shilliday, Peng Wang, R. Ian Storer. Optimization of Potent Ligands for the E3 Ligase DCAF15 and Evaluation of Their Use in Heterobifunctional Degraders, Journal of Medicinal Chemistry. 2024; 67: 5538.  https://doi.org/10.1021/acs.jmedchem.3c02136

14

2024

Inés Montoya-Novoa, José Luis Gardeazábal-Torbado, Andrea Alegre-Martí, Pablo Fuentes-Prior, Eva Estébanez-Perpiñá. Androgen receptor post-translational modifications and their implications for pathology, Biochemical Society Transactions. 2024; 52: 1673.  https://doi.org/10.1042/BST20231082

15

2022

Claudia J. Diehl, Alessio Ciulli. Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders, Chemical Society Reviews. 2022; 51: 8216.  https://doi.org/10.1039/D2CS00387B

16

2022

Zi Liu, Mingxing Hu, Yu Yang, Chenghao Du, Haoxuan Zhou, Chengyali Liu, Yuanwei Chen, Lei Fan, Hongqun Ma, Youling Gong, Yongmei Xie. An overview of PROTACs: a promising drug discovery paradigm, Molecular Biomedicine. 2022; 3: 46.  https://doi.org/10.1186/s43556-022-00112-0

17

2023

Miroslav Peřina, Márton A. Kiss, Gergő Mótyán, Eva Szczyrbová, Martin Eliáš, Vladimír Študent jr, Daniela Kurfürstová, Markéta Kovalová, Lukáš Mada, Jan Bouchal, Éva Frank, Radek Jorda. A-ring-fused pyrazoles of dihydrotestosterone targeting prostate cancer cells via the downregulation of the androgen receptor, European Journal of Medicinal Chemistry. 2023; 249: 115086115086.  https://doi.org/10.1016/j.ejmech.2023.115086

18

2023

Mayuri P Kannan, Sarojini Sreeraman, Chaitanya S Somala, Raja BS Kushwah, Saravanan K Mani, Vickram Sundaram, Anand Thirunavukarasou. Advancement of Targeted Protein Degradation Strategies As Therapeutics for Undruggable Disease Targets, Future Medicinal Chemistry. 2023; 15: 867.  https://doi.org/10.4155/fmc-2023-0072

19

2025

Dongha Kim, Hye Jin Nam, Sung Hee Baek. Ubiquitination of transcription factors in cancer: unveiling therapeutic potential, Molecular Oncology. 2025; 1878-0261.70033.  https://doi.org/10.1002/1878-0261.70033

20

2022

Sinan Ma, Jianai Ji, Yuanyuan Tong, Yuxuan Zhu, Junwei Dou, Xian Zhang, Shicheng Xu, Tianbao Zhu, Xiaoli Xu, Qidong You, Zhengyu Jiang. Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope, Acta Pharmaceutica Sinica B. 2022; 12: 2990.  https://doi.org/10.1016/j.apsb.2022.02.022

21

2025

Simon C. C. Lucas, Yong Xu, Sarah Hewitt, Gavin W. Collie, Lucia Fusani, Ganesh Kadamur, Thomas E. Hadfield, Nancy Su, Caroline Truman, Sylvain Demanze, Haie Hao, Christopher Phillips. Discovery of a Series of Covalent Ligands That Bind to Cys77 of the Von Hippel–Lindau Tumor Suppressor Protein (VHL), ACS Medicinal Chemistry Letters. 2025; 16: 693.  https://doi.org/10.1021/acsmedchemlett.4c00582

22

2024

Eduardo Silva Ramos, Todd M. Greco, Ileana M. Cristea, Erich E. Wanker. 2024; 159.  https://doi.org/10.1016/B978-0-323-95672-7.00016-9

23

2022

Hang Luo, Li Wu, Yujian He, Chong Qin, Xinjing Tang. Major Advances in Emerging Degrader Technologies, Frontiers in Cell and Developmental Biology. 2022; 10: 921958.  https://doi.org/10.3389/fcell.2022.921958

24

2024

Peter D. Zang, Allen Seylani, Evan Y. Yu, Tanya B. Dorff. PROTACing the androgen receptor and other emerging therapeutics in prostate cancer, Expert Review of Anticancer Therapy. 2024; 24: 829.  https://doi.org/10.1080/14737140.2024.2379913